Surgery With or Without Heat Ablation for Several Lung Cancers Found Together
Compares two ways of treating multiple primary lung cancers in the same lung.
Plain-language title generated from the registry record
Registry title: Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
Key facts
- Where
- Beijing, Shenzhen, and Taiyuan, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with two or more primary lung cancers found at the same time in the same lung, who can have thoracoscopic surgery and are in good general health.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Two or more primary lung cancers in the same lung, found at the same time and confirmed by a team of specialists. No distant spread and no N2 or N3 lymph node involvement.
- Earlier treatment
- No previous lung surgery.
- Biomarker or test result
- Lung function (FEV1) of at least 50% of the predicted value before surgery. Performance status of 0 or 1.
Main reasons for not taking part
- Cancer that has spread far away, or N2 or N3 lymph node involvement
- Severe heart or lung problems that rule out the planned surgery, anesthesia or ablation
- Previous lung surgery
- Pregnancy or breastfeeding
- Bleeding disorder, uncontrolled lung infection or active lung tuberculosis
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07819669, who can take part
Where in China
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union MedicalBeijing, ChinaContact: Fengwei TanNo longer taking part
- National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeShenzhen, ChinaContact: Baihua ZhangNo longer taking part
- Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical UniversityTaiyuan, ChinaContact: Xiaofei ZhuangNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Trial code
- NCT07819669
- Record updated
- 15 September 2026
- Original description
This multicenter randomized controlled trial will compare two surgical approaches for patients with synchronous ipsilateral multiple primary lung cancer, meaning two or more primary lung cancers diagnosed at the same time in the same lung. The study aims to determine whether combining thoracoscopic resection with radiofrequency ablation can preserve more lung function while maintaining acceptable tumor control and safety compared with thoracoscopic resection alone.Read full original descriptionShow less
A Multicenter Randomized Controlled Trial of Video-Assisted Thoracoscopic Resection Combined With Intraoperative Radiofrequency Ablation Versus Video-Assisted Thoracoscopic Resection Alone for Synchronous Multiple Primary Lung Cancer
This multicenter randomized controlled trial will compare two surgical approaches for patients with synchronous ipsilateral multiple primary lung cancer, meaning two or more primary lung cancers diagnosed at the same time in the same lung. The study aims to determine whether combining thoracoscopic resection with radiofrequency ablation can preserve more lung function while maintaining acceptable tumor control and safety compared with thoracoscopic resection alone.
A total of 160 participants will be randomly assigned in a 1:1 ratio to one of two groups. In the combined-treatment group, the main lung lesion will be removed by video-assisted thoracoscopic surgery, and the secondary lesion will be treated with intraoperative computed tomography-guided radiofrequency ablation. In the surgery-alone group, both the main and secondary lesions will be removed by video-assisted thoracoscopic surgery.
The primary outcome is the change in forced expiratory volume in one second (FEV1), a standard measure of lung function, from baseline to 6 months after surgery. Other outcomes include local recurrence, treatment-related complications, disease-free and overall survival, length of hospital stay, medical costs, quality of life, patient satisfaction, and the change in postoperative lung volume compared with preoperative lung volume, as quantitatively measured using three-dimensional chest computed tomography reconstruction. Participants will be followed at approximately 1, 3, 6, 12, and 24 months after surgery.
Inclusion: Age 18 to 80 years, inclusive; Diagnosis of synchronous ipsilateral multiple primary lung cancer based on imaging and/or biopsy findings and confirmed by a multidisciplinary team; The main lesion is considered suitable for video-assisted thoracoscopic lobectomy or sublobar resection, with complete resection anticipated; The secondary lesion is considered suitable for both video-assisted thoracoscopic sublobar resection and intraoperative CT-guided radiofrequency ablation; Eastern Cooperative Oncology Group performance status of 0 or 1; Preoperative forced expiratory volume in 1 second of at least 50% of the predicted value; Ability to understand the study requirements and willingness to provide written informed consent.
Exclusion: Previous pulmonary surgery; Distant metastatic disease or N2 or N3 lymph node involvement; Severe cardiac or pulmonary dysfunction that would preclude the planned surgery, anesthesia, or radiofrequency ablation; Active bleeding disorder or severe coagulation abnormality; Uncontrolled pulmonary infection or active pulmonary tuberculosis; Pregnancy or breastfeeding; The secondary lesion cannot be safely accessed using the intraoperative CT-guided radiofrequency ablation system; The secondary lesion is adjacent to a major blood vessel or another critical structure such that radiofrequency ablation is considered unsafe or unsuitable.